Biotechnology firms operate in a highly innovative and capital-intensive environment, characterized by high levels of R&D, long product development periods, significant regulations, and high levels of uncertainty. These firms rely heavily on intangible assets, such as intellectual capital and innovation. Consequently, intellectual capital and innovation activities play a crucial role in financial strategies and capital structure decisions. This study aims to examine how intellectual capital and innovation activity influence capital structure decisions of biotech firms in Sweden. In this paper, financial data of 1528 companies from 2012 to 2022 were analyzed. Using logistic regression modeling, the results showed that biotech firms with higher intellectual capital are more likely to issue equity whereas those with greater innovation activity tend to rely more on debt financing. These findings underscore the complexities of financial strategy in the biotech sector, emphasizing the need for flexible capital structure management. Moreover, policymakers should focus not only on equity availability but also on ensuring access to debt financing, as both are crucial for sustaining biotech innovation and growth.